Revised: 26 January 2026

Safety Information

Medsafe Safety Communications

Recent safety communications

Date Communication Product Type Topic
26 January 2026 Monitoring Medicine M² logo Glucagon-like peptide-1 receptor agonists (dulaglutide, liraglutide, semaglutide, tirzepatide) and acute persistent visual loss
15 December 2025 Monitoring Medicine M² logo Atomoxetine and the possible risk of gynaecomastia 
11 November 2025 Monitoring Medicine Further Update - Estradot (estradiol) transdermal patches: reports of quality and efficacy
4 November 2025 Monitoring Medicine Update - Estradot (estradiol) transdermal patches: reports of quality and efficacy
22 October 2025 Monitoring Medicine Estradot (estradiol) transdermal patches: reports of quality and efficacy
23 September 2025 Alert Medicine Topiramate: New measures and advice to prevent exposure during pregnancy
31 July 2025 Monitoring Medicine M² logo Update - Anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, obinutuzumab, ofatumumab) and the possible risk of pyoderma gangrenosum
22 July 2025 Alert Medicine Warning: advertisements claiming Medsafe approval or bearing the Medsafe logo are scams
30 May 2025 Alert Device Stop using Euky Bear Warm Steam Vaporiser – model number EBSV2013
14 April 2025 Monitoring Medicine M² logo Update - Direct acting oral anticoagulants and potential for patients to experience mood changes (monitoring closed February 2025)
9 April 2025 Alert Medicine Use of carbamazepine during pregnancy: Growth risks for babies
1 April 2025 Alert Medicine Ayurvedic medicines update
27 February 2025 Monitoring Medicine Update - Reports of pericarditis following mpox vaccination
16 January 2025 Monitoring Medicine M² logo Anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, obinutuzumab, ofatumumab) and the possible risk of pyoderma gangrenosum

Archive of safety communications

What are Medsafe safety communications?

These communications are intended to help consumers and healthcare professionals make informed decisions about their use of medicines and medical devices.

Medicines and medical devices provide important benefits for consumers but no product is completely safe. Whilst many risks are identified before the product is used in New Zealand some are identified later.

The known risks associated with medicines in New Zealand are outlined in the consumer medicine information (CMI) and the data sheet. The known risks for medical devices are generally outlined in the product information/user manual. Your healthcare professional can also provide help and assistance on how to use medicines or medical devices. Further information may be found on the product packaging or the company supplying the medicine or medical device may operate a helpline.

There are two types of Medsafe safety communications.

  1. Monitoring communications
  2. Alert communications

Anyone can subscribe to receive Medsafe safety communications.

How do I subscribe to receive Medsafe safety communications?

Monitoring Communications

These communications are intended to provide information to consumers and healthcare professionals about newly identified potential safety concerns.

In some cases, these communications are issued to request further information from users. Safety concerns for medicines for which Medsafe is actively seeking further reports display this symbol: M² logo

No actions are generally advised, other than to follow the instructions provided with the medicine or medical device. Consumers should NOT stop using a medicine or medical device following a monitoring communication. Healthcare professionals should not change a patient's treatment because of a monitoring communication.

Not all of these concerns will result in an action. This is because after an investigation, Medsafe may not consider that there is a link between the events and the medicine or medical device. Medsafe may reinvestigate the concern if more information is identified at a later date.

Alert Communications

Alert communications are issued once a review of the safety concern is complete. Alerts contain more information on the safety concern and provide specific advice on actions that may need to be taken by healthcare professionals and consumers.

Even though an alert has been issued it does not necessarily mean that a medicine or medical device is considered to be unsafe.

Safety concerns which identify defective medicines or medical devices supplied in the market may result in a recall action. This can include removal of the product from supply or undertaking corrective action. Recent recall actions initiated in New Zealand are published in the Medsafe Online Recalls Database (MORD).

Search the Medsafe Online Recall Database (MORD)

Further Information

Further information on the development of the Medicines Monitoring scheme M² Logo and Medsafe's safety monitoring processes can be found in the following links.

What is the Medicines Monitoring scheme M² Logo?

How does Medsafe monitor medicine safety?

How does Medsafe monitor the safety and quality of medical devices?

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /